Results 161 to 170 of about 16,655 (259)

Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR Registry. [PDF]

Can J Kidney Health Dis
McFarlane P, Bichet DG, Alam A, Bubolic S, Laplante A.   +4 more
europepmc   +1 more source

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study [PDF]

, 2007
Andreas L. Serra, Andreas D. Kistler, Diane Poster, Marian Struker, Rudolf P. Wüthrich, Dominik Weishaupt, Frank T. C. Tschirch   +6 more
openalex   +1 more source

Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease: Design and baseline characteristics. [PDF]

Am J Nephrol
Seliger SL, Wang W, Watnick T, George D, Diggs C, West M, Nowak K, Ostrow A, You Z, Gitomer B, Chonchol M.   +10 more
europepmc   +1 more source

#1471 A novel CT-based radiomics approach for kidney function evaluation in ADPKD [PDF]

Luca Calvaruso, Pierluigi Fulignati, Luigi Larosa, Huong Elena Tran, Claudio Votta, Carla Cipri, Luigi Natale, Viola D’Ambrosio, Giulia Condello, Francesco Pesce, Luca Boldrini, Giuseppe Grandaliano   +11 more
openalex   +1 more source

Natural history of simple and complex cysts in autosomal dominant polycystic kidney disease on MRI. [PDF]

Commun Med (Lond)
Hu Z, Li C, Blumenfeld JD, Prince MR.
europepmc   +1 more source

Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan. [PDF]

Medicina (Kaunas)
Jankowska Z, Niemczyk M.
europepmc   +1 more source

Catheter-Based Renal Denervation in ADPKD: Just for Pain Control? [PDF]

, 2014
ESPOSITO, GIOVANNI, PISANI, ANTONIO, Riccio E, SABBATINI, MASSIMO   +3 more
core   +1 more source

PERADIGM: Phenotype embedding similarity-based rare disease gene mapping. [PDF]

PLoS Genet
Zheng W, Xie Y, Gu J, Li H, Somlo S, Besse W, Zhao H.   +6 more
europepmc   +1 more source

In silico approaches for pathogenicity prediction of missense variants of uncertain significance (VUS) in ADPKD

, 2016
Parnthanutcha Wetchanien, Duangkamon Bunditworapoom, Manop Pithukpakorn, Chanin Limwongse, Kriengsak Vareesangthip, Anunchai Assawamakin, Wanna Thongnoppakhun   +6 more
openalex   +1 more source

KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary

Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, Godela Brosnahan, Melissa A. Cadnapaphornchai, Arlene B. Chapman, Émilie Cornec-Le Gall, Joost P.H. Drenth, Ron T. Gansevoort, Peter C. Harris, Tess Harris, Shigeo Horie, Max C. Liebau, May Y. Liew, Andrew J. Mallett, Changlin Mei, Djalila Mekahli, Dwight Odland, Albert Ong, Luiz F. Onuchic, York Pei, Ronald D. Perrone, Gopala K. Rangan, Brian Rayner, Roser Torrá, Ethan M. Balk, Craig E. Gordon, Amy Earley, Reem A. Mustafa, Olivier Devuyst   +29 more
openalex   +2 more sources